Use of intramyometrial injection of prostaglandin F 2 alpha in the management of intractable hemorrhage due to uterine atony.
Prostaglandin F2 alpha, in doses varying from 1 to 5 mg was injected transabdominally, transvaginally or intraabdominally (during caesarean section) into the myometrium in ten patients affected by metrorrhagias not responsive to conventional uterotonic drugs. In all cases but one the result was excellent. Important side effects were observed in only one patient, because of the inadvertent intravascular injection of 5 mg Prostaglandin into the endocervix. An adequate treatment of this patient brought her to complete recovery in a short time. According to our experience, the intramyometrial injection of PGF2 alpha, in doses varying from 1 to 2 mg, is a simple, safe and effective method in the control of severe hemorrhage due to uterine atony not responding to conventional treatment.
D000293:Adolescent; D000328:Adult; D015237:Dinoprost; D005260:Female; D006801:Humans; D008755:Methylergonovine / Q000627:therapeutic use; D008875:Middle Aged; D009215:Myometrium; D010121:Oxytocin / Q000627:therapeutic use; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000209:etiology; D011460:Prostaglandins F / Q000008:administration & dosage / Q000627:therapeutic use*; D014590:Uterine Contraction; D014592:Uterine Hemorrhage / Q000188:drug therapy* / Q000209:etiology
D011460:Prostaglandins F; D010121:Oxytocin; D015237:Dinoprost; D008755:Methylergonovine